… This study provides an opportunity to address the knowledge gaps identified above. In the
… groups of cancer patients enrolled in the Hokusai VTE Cancer study, including patients with …

… management of cancer-associated venous thromboembolism. The aim of this study was to
assess the efficacy and safety of edoxaban … The Hokusai-VTE Cancer trial is currently ongoing …

… In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the … of
recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients with cancer-…

… The Hokusai VTE Cancer trial compared edoxaban with dalteparin for VTE treatment in
patients with active cancer. … of the Hokusai VTE Cancer trial who have made this study possible. …

… the treatment of cancer-associated venous thromboembolism … Hokusai VTE Cancer trial to
compare the oral factor Xa inhibitor edoxaban with subcutaneous dalteparin for the treatment …

… study demonstrated that 12 months of edoxaban treatment … The Hokusai VTE Cancer trial
showed that the rate of major … edoxaban treatment group of cancer-associated VTE. The current …

… and management, can vary with respect of cancer type and … Hokusai-VTE cancer trial MB
was increased in the edoxaban … in cancer patients enrolled in the Hokusai-VTE cancer trial …

… asymptomatic venous thromboembolism (VTE), deep vein thrombosis (DVT… Hokusai VTE
Cancer study, which included patients who were given heparin administration before edoxaban …

… their use in such patients. The Hokusai VTE Cancer study shows that edoxaban is non-inferior …
of higher major bleeding namely in patients with gastrointestinal cancer. Although further …

… patients with a standard dose of edoxaban in the current study than in those in the Hokusai-VTE
Cancer study… the study populations including the cancer status and the races. A previous …